Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px
Document › Details

Cytos Biotechnology AG. (5/8/15). "Press Release: Cytos’ Bond Conversion into Equity Effective. 77.49 Million Shares Newly Issued in Exchange for Convertible Bonds". Schlieren.

Organisations Organisation Cytos Biotechnology AG
  Today Kuros Biosciences AG (SIX: KURN)
  Group Kuros (Group)
  Organisation 2 SIX Swiss Exchange AG
Products Product BIOTECH
  Product 2 investment banking
Index term Index term Cytos Biotechnology–SEVERAL: investment, 201505 conversion of all outstanding convertible bonds into 77.49m new shares making Cytos debt free
Person Person Welten, Harry (Cytos Biotechnology 201203 CFO)
     


- First day of trading of new shares originally scheduled for May 11, 2015 but due to mistake from SIS AG already possible on May 8, 2015


Cytos Biotechnology Ltd (“Cytos”) today announced that the convertible bond restructuring has been completed with effect as of May 8, 2015. As a result, 77'490'000 shares have been issued on top of the 30'525'276 shares already issued and outstanding. Hence, the total number of shares issued and outstanding now amounts to 108'015'276 shares. All newly issued shares were originally scheduled to be free for trading starting Monday, May 11, 2015 and are equal to those already issued and listed at the SIX Swiss Exchange. However, due to a mistake by SIS AG, certain shares were already possible to trade on May 8, 2015 as per message below.

As announced previously, all claims from the convertible loan note holders are eliminated upon the bonds conversion into equity. As a result, Cytos is free of any debt going forward with immediate effect.


Message from SIS AG:

Quote

Switzerland: Friday, 8 May 2015: De-blocking of a shares Cytos Biotechnology AG, Schlieren

Due to a technical error the new shares of Cytos Biotechnology, ISIN CH0011025217, resulting from the mandatory conversion 5.75 % Cytos Biotechnology (ISIN CH0029060735) have been de-blocked already today around 9.00 CET, 8 May 2015 instead of 11 May 2015. Realizing the mistake the decision was taken to keep the shares de-blocked.

We apologize for any inconvenience caused and thank you for your understanding.

Yours faithfully SIX SIS Ltd

Unquote


For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

Cytos Biotechnology AG Wagistrasse 25 8952 Schlieren Switzerland
Tel: +41 44 733 47 47 Fax: +41 44 733 47 40 info@cytos.com www.cytos.com


About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.


Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
www.cytos.com

   
Record changed: 2016-04-23

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Kuros (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top